All In Biotech

Drug Trial Radar · NCT04771130

A Study of BGB-11417 in Participants With Myeloid Malignancies

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

May 24, 2021

Primary completion

Aug 31, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Feb 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasm

Interventions

  • BGB-11417Drug

    Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.

  • AzacitidineDrug

    Intravenous or subcutaneous administration for 7 days.

  • PosaconazoleDrug

    Oral administration for 8 days on second cycle only.

  • BGB-11417Drug

    Oral administration for 28 days on a 28-day cycle.

  • BGB-11417Drug

    Oral administration for 10, 14 or 21 days on a 28-day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs)
  2. Part 1 And 2: Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Approximately 24 months
  3. Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) RateTime frame: Approximately 24 months
  4. Part 3 MDS Cohort: Modified Overall Response (mOR) RateTime frame: Approximately 24 months
  5. Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to the last quantifiable timepoint (t) (AUC0-t) Of BGB-11417 When Administered Alone and when Co-administered With PosaconazoleTime frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)
  6. Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Administered Alone and When Co-administered With PosaconazoleTime frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)
  7. Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to infinity (AUC0-infinity) Of BGB-11417 When Administered Alone and When Co-administered With PosaconazoleTime frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, , 4, 6, 8, and 24 hours postdose)
  8. Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number Of Participants Experiencing DLTsTime frame: Cycle 2
  9. Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number of Participants Experiencing TEAEsTime frame: Approximately 24 months

Locations

47 sites in 10 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Terminated

  • Tampa General Hospital

    Tampa, Florida · Recruiting

  • Upmc Hillman Cancer Center(Univ of Pittsburgh)

    Pittsburgh, Pennsylvania · Recruiting

  • Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Recruiting

  • St George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • Orange Health Hospital

    Orange, New South Wales, Australia · Recruiting

  • Gold Coast University Hospital

    Southport, Queensland, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • One Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Peking University Peoples Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Recruiting

  • Guangdong Provincial Peoples Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The Second Peoples Hospital of Shenzhen

    Shenzhen, Guangdong, China · Completed

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University Branch Donghu

    Nanchang, Jiangxi, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Completed

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Hopital Claude Huriez Chu Lille

    Lille, France · Recruiting

  • Hopital Larchet

    Nice, France · Recruiting

  • Hopital Saint Louis

    Paris, France · Recruiting

  • Universitaetsklinikum Leipzig Aor

    Leipzig, Germany · Recruiting

  • Universitaetsklinikum Ulm

    Ulm, Germany · Recruiting

  • Policlinico Sorsola Malpighi, Aou Di Bologna

    Bologna, Italy · Recruiting

  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst

    Meldola, Italy · Recruiting

  • Niguarda Cancer Center Division of Hematology

    Milan, Italy · Recruiting

  • North Shore Hospital

    Auckland, New Zealand · Recruiting

  • Aotearoa Clinical Trials

    Auckland, New Zealand · Recruiting

  • Wellington Regional Hospital (Ccdhb)

    Wellington, New Zealand · Recruiting

  • Samsung Medical Center

    GangnamGu, Seoul Teugbyeolsi, South Korea · Recruiting

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.